| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Regeneron Pharmaceuticals is making significant strides in product development, particularly with the successful clinical outcomes of Dupixent, which enhances their potential for market approval. Continued innovations in allergy treatments and robust research and development efforts indicate a strong pipeline that may positively impact stock performance. Investor confidence is bolstered by participation in key conferences, signaling ongoing advancements in their product line. However, regulatory challenges and market competition could hinder the pace of product approvals and development. |
| The price action of Regeneron Pharmaceuticals (REGN) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for REGN since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.2, and the negative at -0.2 on 2025-11-07. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (1.4) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| REGN | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 | 0%(0%) | 0 | 0% | 0.1 | 1.4 | -1 | |||||||
| 2025-11-06 | 0%(0%) | 0 | 0% | -0.1 | 0.3 | -1 | |||||||
| 2025-11-05 | 0%(0%) | 0 | 0% | -0.1 | 0.5 | -1 | |||||||
| 2025-11-04 | 0%(0%) | 0 | 0% | -0.1 | 0.4 | -1 | |||||||
| 2025-11-03 | 0%(0%) | 0 | 0% | 0.1 | 1.6 | -1 | |||||||
| 2025-11-02 | 0%(0%) | 0 | 0% | 0.2 | 1.9 | -1 | |||||||
| 2025-11-01 | 0%(0%) | 0 | 0% | 0.2 | 1.9 | -1 | |||||||
| 2025-10-31 | 0%(0%) | 0 | 0% | 0.2 | 1.9 | -1 | |||||||
| 2025-10-30 | 0%(0%) | 0 | 0% | 0.2 | 2.1 | -1 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.3 | 2.5 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-07 17:08:24 Dupixent's effectiveness in treating allergic fungal rhinosinusitis represents innovation in allergy treatment options. |
| 2025-11-07 17:08:24 The ongoing research behind Regeneron's treatments highlights advancements in understanding and addressing complex health issues. |
| 2025-11-07 17:08:24 The acceptance of the sBLA for FDA priority review signals a significant regulatory milestone for Regeneron. |
| 2025-11-07 17:08:24 Regeneron's stock has shown positive movement, reflecting investor confidence and market performance. |
| 2025-11-07 17:08:24 Regeneron's Dupixent has successfully met key clinical endpoints, indicating effectiveness and potential for new market approval. |